XOMA (XOMA) Investor Presentation - Slideshow

Company Overview - XOMA has a portfolio of over 70 assets across more than 30 disclosed indications[8] - The company focuses on acquiring drug royalties associated with mid- to early-stage clinical candidates, particularly those with blockbuster potential licensed to large-cap partners[8] - XOMA's business model is capital-efficient, with R&D costs borne by partners, and exposure risk is mitigated through a diverse portfolio[8] Portfolio Advancements and Key Assets - Since 2017, XOMA's portfolio has seen over 25 advancements from phase to phase[13] - Roche's faricimab, in which XOMA holds a 0.5% royalty, received FDA approval[16] - XOMA has economic rights from Affitech SA[9, 12] Financial and Operational Highlights - XOMA acquired economic interest in Roche's faricimab from Affitech for $6 million upfront[40] - The company completed over $60 million in Perpetual Preferred Stock Offerings[40] Partner-Driven Clinical Events - Novartis launched a Phase 3 study for NIS793 and is conducting multiple Phase 2 trials for iscalimab[45] - Janssen launched a Phase 3 study for cetrelimab[45] Potential Milestones - XOMA's portfolio has over $1 billion in potential milestones[50, 52, 62, 65]